SciClone Pharmaceuticals, Inc. - Securities Class Action

Company and Case Information

IMPORTANT INFORMATION | INDEX OF FILINGS | SEARCH

Home

Index of Filings

News and Press Releases

Filings

Decisions

Settlements

Litigation Activity Indices

Top Ten List

Annual/Quarterly Updates

Clearinghouse Research

Articles & Papers

Search

Related Sites

About Us

Local Rules

Sponsors

Register

_______________
Copyright (c) 2001
Stanford Law School

SciClone Pharmaceuticals, Inc. Summary: According to a press release dated August 13, 2010, the Complaint alleges that the defendants engaged in the development and commercialization of therapeutics for the treatment of cancer and infectious diseases in the People's Republic of China and internationally. Its principal product is ZADAXIN for the treatment of hepatitis B and hepatitis C viruses and certain cancers, as well as for use as a vaccine adjuvant or as a chemotherapy adjuvant for cancer patients with weakened immune systems. Throughout the Class Period, SciClone claimed to have commercialization rights for DC Bead, a product candidate for the treatment of advanced liver cancer in China, as well as for ondansetron RapidFilm, an oral thin film formulation of ondansetron to treat and prevent nausea and vomiting caused by chemotherapy, radiotherapy, and surgery in China and Vietnam.

The Complaint alleges that throughout the Class Period, defendants were engaged in illegal and improper sales and marketing activities in China and abroad regarding its products. This ultimately caused the Company to become the focus of a joint investigation by the Securities and Exchange Commission ("SEC") and the Department of Justice ("DOJ") for possible violations of the Foreign Corrupt Practices Act ("FCPA"). It was only at the end of the Class Period, however, that investors ultimately learned the truth about the Company's operations after it was reported that the SEC and DOJ were investigating the Company for violations of the FCPA. At that time, shares of the Company declined almost 40% in the single trading day, on abnormally large trading volume.

On October 27, 2010, Judge James Ware signed the order consolidating two related actions under "In re SciClone Pharmaceuticals Securities Litigation,” case number 10-CV-03584. The Court appointed Plaintiffs George Berneshawi and Luciano Garzelli as Lead Plaintiffs and Kahn Swick & Foti LLC and Brower Piven as Co-Lead Counsel. The amended complaint shall be filed on or before November 29, 2010.

On November 24, 2010, the lead plaintiffs filed a Stipulation of Voluntary Dismissal, which was signed by Judge James Ware on December 1, 2010. The case is now dismissed without prejudice.

INDUSTRY CLASSIFICATION:
SIC Code: 2834
Sector: Healthcare
Industry: Biotechnology & Drugs

COMPANY/ISSUER NAME:	SciClone Pharmaceuticals, Inc.
COMPANY/ISSUER TICKER:	SCLN
COMPANY WEBSITE:	www.sciclone.com

FIRST IDENTIFIED COMPLAINT IN THE DATABASE

Alan C. Lewis, et al. v. SciClone Pharmaceuticals, Inc., et al.

COURT: N.D. California	DOCKET NUMBER: 10-CV-03584
JUDGE NAME: Hon. James Ware
DATE FILED: 08/13/2010	SOURCE:
CLASS PERIOD START: 05/11/2009	CLASS PERIOD END: 08/10/2010
TYPE OF COMPLAINT: Complaint (Unamended and Unconsolidated)
PLAINTIFF FIRMS NAMED IN COMPLAINT:
Barroway Topaz Kessler Meltzer & Check, LLP (San Francisco) 580 California Street, Suite 1750, San Francisco, CA, 94104 (voice) 415.400.3000, (fax) 415.400.3000, info@btkmc.com Kahn Swick & Foti, LLC (Madisonville) 206 Covington Street, Madisonville, LA, 70447 (voice) (504) 455-1400, (fax) (504) 455-1498, Kahn Swick & Foti, LLC (Updated New York) 500 Fifth Avenue, Ste. 1810, New York, NY, 10110 (voice) 212.696.3730, (fax) 504.455-1498, _____________________________________________ TOTAL NUMBER OF PLAINTIFF FIRMS: 3

DOCUMENTS FOR THE FIRST IDENTIFIED COMPLAINT
Class Action Complaint for Violations of Federal Securities Laws - Jury Trial Demanded
Type: Complaint		Date on the document: 08/13/2010
Declaration Of Kim Miller In Support Of Motion Of Lead Plaintiff Movant George Berneshawi For Consolidation Of All Related Cases, Appointment Of Lead Plaintiff And Approval Of Selection Of Lead Plaintiff's Choice Of Counsel
Type: Declaration		Date on the document: 10/12/2010
Notice Of Motion And Motion Of George Berneshawi For Consolidation Of All Related Cases, Appointment Of Lead Plaintiff, And Approval Of Lead Plaintiff's Choice Of Counsel; Memorandum Of Points And Authorities In Support Thereof
Type: Motion		Date on the document: 10/12/2010
Proposed Order Consolidating All Related Cases, Appointing Lead Plaintiff And Approving Lead Plaintiff's Choice Of Counsel
Type: Order		Date on the document: 10/12/2010
Joint Case Management Statement
Type: Other		Date on the document: 10/21/2010
Stipulation And [Proposed] Order Regarding Case Schedule
Type: Order		Date on the document: 10/21/2010
Order Consolidating Cases; Appointing Lead Class Plaintiffs And Lead Class Counsel; Scheduling Order
Type: Order of Consolidation		Date on the document: 10/27/2010
Stipulation Of Voluntary Dismissal Without Prejudice Pursuant To Fed. R. Civ. P. 41(a)(1)
Type: Other		Date on the document: 11/24/2010
Stipulation Of Voluntary Dismissal Without Prejudice Pursuant To Fed. R. Civ. P. 41(a)(1)
Type: Order		Date on the document: 12/01/2010
U.S. District Court Civil Docket
Type: Docket		Date on the document: 12/01/2010

OTHER DOCUMENTS
Class Action Complaint For Violations Of Federal Securities Laws
Case Name and/or Number: Mariano Karner, et al. v. SciClone Pharmaceuticals, Inc., et al.
Type: Complaint		Date on the document: 09/07/2010

WARNING AND DISCLAIMER OF LIABILITY:
The information included on this Web site, whether provided by personnel employed by Stanford Law School or by third parties, is provided for research and teaching purposes only. Neither Stanford University, Stanford Law School, nor any of their employees, agents, contractors, or affiliates warrant the accuracy or completeness of the information or analyses displayed herein, and we caution all readers that inclusion of any information on this site does not constitute an endorsement of the truthfulness or accuracy of that information. In particular, this Web site contains complaints and other documents filed in federal and state courts, which make allegations that may or may not be accurate. No reader should, on the basis of information contained in or referenced by this Web site, assume that any of these allegations are truthful.

Go to Search page | Go to Case Index page | Back to Top

�